Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

To be part of this study, you must have been recently diagnosed with multiple myeloma and have already had initial treatment, including a stem cell transplant. Your cancer must have improved after your first treatment, showing at least a partial response, and not gotten worse since then. You also shouldn't have had any maintenance treatment for multiple myeloma yet.

There are also some health requirements. For example, you need to be generally well enough to take part, as shown by certain health checks. Your blood test results must be within an acceptable range, and you shouldn't have any serious side effects from previous lenalidomide treatment that made you stop taking it.

People who have previously received certain types of cancer treatments or therapies that specifically target a protein called BCMA (which is involved in multiple myeloma) usually cannot join this study. Also, if your multiple myeloma got worse at any point before this study, or if you've recently had a live vaccine, you might not be eligible. The study is open to both men and women, aged 18 and over.

The detailed information on what taking part involves is not provided in the summary. However, in a typical Phase 3 study like this, you would be randomly assigned to one of the treatment groups (teclistamab alone, teclistamab plus lenalidomide, or lenalidomide alone). You would receive your assigned treatment for a period determined by the study. This would involve regular visits to the clinic for check-ups, blood tests, and to receive your medication. There would also be follow-up appointments to monitor your health and the effects of the treatment. The total duration of the study, including treatment and follow-up, would be fully explained by the study team.